Heart Health: What the Evidence Actually Shows

Roughly half of first heart attacks happen to people whose cholesterol panel looked fine. That is not a failure of the patients. It is a failure of what we were measuring.

Presented By Our Partners

Cardiovascular disease remains the leading cause of death in nearly every developed country, and it has held that position through decades of statin prescribing, dietary campaigns, and public health messaging. The drugs work. The messaging is mostly correct. And yet a substantial fraction of people who have heart attacks were told, using the standard tools, that they were at low risk.

The past three years have made the reason clearer. The conventional risk calculation was built around a handful of modifiable factors that are easy to measure. It was never designed to catch genetic risk, structural disease already present, or the slow accumulation of damage that shows up nowhere on a lipid panel. Three separate lines of research have converged on that gap.

A standard cholesterol panel misses a genetic risk factor in one of five people

Lipoprotein(a) is an LDL-like particle with an extra protein attached. Your level is set almost entirely by genetics, stays roughly constant across your life, and is not meaningfully changed by diet, exercise, or statins. Around one in five people carries an elevated level, and the great majority of them have never been tested.

This is not a fringe marker. Elevated Lp(a) is an independent causal risk factor for atherosclerotic disease and aortic stenosis, and it explains a meaningful share of the heart attacks that occur in people with unremarkable LDL. Someone can eat well, exercise, take a statin, achieve a textbook lipid panel, and still carry substantially elevated risk that nothing in their care has addressed.

What changed recently is that it became actionable. The 2026 ACC/AHA dyslipidemia guidelines moved Lp(a) toward routine measurement, and several drugs designed specifically to lower it are moving through late-stage trials. For decades there was little reason to test for something nobody could treat. That argument no longer holds.

It is a one-time test. Because the level is genetically determined and stable, a single measurement tells you what you need to know for life.

More on lipids and genetic risk:

• The Lp(a) Reckoning: How the 2026 ACC/AHA Guidelines Rewrote the Rules
• Lp(a): The Genetic Risk Factor Statins Cannot Touch
• Lipoprotein(a): The Hidden Genetic Risk Finally Becoming Treatable
• One Shot to Silence Heart Disease: CRISPR Gene Editing and Cholesterol
• The Omega 3 Index: Twenty Years of Research on a Blood Marker

A calcium score shows you the disease instead of estimating the odds

Every risk calculator does the same thing: it takes population data and produces a probability. Useful, but it is a statistical statement about people like you, not a statement about you.

A coronary artery calcium scan does something categorically different. It is a low-dose CT that looks directly at your coronary arteries and measures calcified plaque. It is not predicting whether you might develop atherosclerosis. It is reporting whether you already have it.

The most useful result is the lowest one. A score of zero carries such a favorable near-term prognosis that the finding has its own name in the cardiology literature, the power of zero. It frequently reclassifies people the risk calculator flagged as intermediate, in both directions: some are reassured, some discover disease that no risk factor predicted.

A third source of hidden risk sits in the blood itself. Clonal hematopoiesis of indeterminate potential, where blood stem cells acquire mutations that expand with age, turns out to drive cardiovascular risk through inflammation. It is a mechanism that sits entirely outside the cholesterol framework, and it links heart disease to hematology in a way nobody anticipated a decade ago.

More on imaging and hidden risk:

• The Power of Zero: Coronary Artery Calcium Scoring
• The Mutations Hiding in Your Blood: Clonal Hematopoiesis and Heart Disease
• Microplastics in the Human Body: Cardiovascular and Brain Evidence
• What the Latest Heart Research Means for Patients in 2026

Cardiorespiratory fitness outperforms nearly every other modifiable factor

If you could know only one number about someone and had to predict how long they would live, the evidence suggests you should ask for their VO2 max rather than their cholesterol, their blood pressure, or their weight.

An analysis spanning millions of person-years found that cardiorespiratory fitness predicted all-cause mortality more strongly than the traditional risk factors, and that the gap between the bottom fitness category and the one just above it was larger than the gap between any other two adjacent categories. The steepest benefit is available to the least fit, which is the opposite of how most people assume this works.

Timing matters more than expected. A Circulation study tracking men from adolescence found that fitness at eighteen predicted cardiovascular events at sixty-five, decades later and after accounting for adult behavior. That does not mean the window closes. It means fitness accumulates.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Muscle belongs in this conversation too. It is the largest site of glucose disposal in the body, which makes resistance training a cardiovascular intervention rather than a cosmetic one.

More on fitness and cardiovascular risk:

• Your VO2 Max May Be the Best Predictor of How Long You Will Live
• Fit at 18, Protected at 65: A Landmark Circulation Study
• Why Muscle Is the Organ of Longevity
• Zone 2 Training and the Mitochondrial Science of Low-Intensity Cardio
• Walking for Longevity: The 7,000 Step Sweet Spot

Heat exposure has better cardiovascular evidence than most supplements

A Finnish cohort has been followed for more than two decades, tracking sauna use against cardiovascular outcomes. The association is unusually strong and dose-dependent: frequent sauna bathing tracks with substantially lower cardiovascular mortality, with more sessions per week associated with greater reduction.

The plausible mechanism is that heat exposure mimics moderate exercise. Heart rate rises, vessels dilate, plasma volume expands, and heat shock proteins are induced. It is not a substitute for training, but it appears to be genuine cardiovascular stress with genuine adaptation.

The honest limitation is that this is observational. Finns who sauna four times a week may differ from Finns who sauna once in ways no adjustment fully captures. Randomized trials of this scale and duration do not exist. What makes the finding hard to dismiss is the consistency of the dose response and the coherence of the mechanism.

Sleep regularity turns out to matter in a similar way. Research on the sleep regularity index found that consistency of bedtime predicted cardiometabolic outcomes more strongly than total sleep duration, which inverts the usual advice.

More on heat, recovery, and cardiovascular health:

• The Sauna Longevity Effect: 25 Years of Finnish Research
• The Heat Prescription: Sauna Data on Heart and Brain
• The Sleep Regularity Reset
• Your Gut Microbiome Is Talking to Your Heart and Kidneys

Diseases that were untreatable a decade ago now have therapies

Cardiac amyloidosis spent most of its history as a diagnosis of exclusion that arrived too late to matter. Misfolded transthyretin protein deposits in heart tissue, the muscle stiffens, and heart failure follows. It was long considered rare, which turned out to be partly an artifact of nobody looking for it.

Both halves of that picture have changed. Imaging improved enough to find it, and a class of ATTR-targeting therapies now alters its course. Suspecting it early is now worth something.

Further out, gene editing has entered cardiovascular medicine. One-time CRISPR approaches to permanently lower cholesterol are in human trials, aiming to replace daily medication with a single intervention. The efficacy signals are real and the long-term safety questions are genuinely open, as they should be for a permanent edit.

The aging biology itself is also under investigation, with work on centenarian genetics and cardiovascular aging and on clearing senescent cells from vascular tissue.

More on cardiovascular treatment and aging:

• The Cardiac Amyloidosis Revolution
• Reversing Cardiovascular Aging: Centenarian Genes and Rapamycin
• Zombie Cells: Senolytics and CAR-T for Aging
• Are GLP-1 Drugs the First True Longevity Medicines?
• When AI Finds the Signal, Medicine Still Has to Finish the Job

Measuring your own cardiovascular signals

Blood pressure and rhythm are now measurable at home with devices that would have been clinical equipment fifteen years ago. The value is in trend data rather than any single reading, because blood pressure varies enough hour to hour that an annual office measurement is a poor sample.

ECG capability has spread furthest. Consumer devices detect atrial fibrillation, a condition that frequently produces no symptoms and substantially raises stroke risk. Finding it early genuinely changes outcomes, which puts these devices in a different category from most wellness technology.

ECG and rhythm monitoring:

• AliveCor KardiaMobile: The Most Affordable FDA Cleared Personal ECG
• AliveCor KardiaMobile 6L: Six-Lead Consumer ECG
• AliveCor KardiaMobile Card
• Apple Watch Series 9: ECG and HRV Monitoring
• Withings ScanWatch: FDA Cleared ECG and SpO2
• Eko Core 500: AI Digital Stethoscope for Murmurs and AFib
• Eko Duo: Digital Stethoscope With Built-In ECG

Blood pressure monitoring:

• Omron Complete: Blood Pressure Monitor With Built-In ECG
• Omron HeartGuide: The First FDA Cleared Wrist BP Watch
• Withings BPM Core
• Withings BPM Connect
• Aktiia Bracelet: 24/7 Cuffless Blood Pressure
• Biobeat BB-613: FDA Cleared Cuffless Monitoring

Wearables with cardiovascular tracking:

• WHOOP 5.0: ECG, Blood Pressure Insights, and Pace of Aging
• Oura Ring Gen 3: What HRV Actually Tells You
• Garmin Fenix 7X Pro: ECG and VO2 Max Tracking
• Apple Watch Ultra 2
• Samsung Galaxy Watch Ultra
• Fitbit Charge 6: Affordable FDA Cleared ECG
• Masimo MightySat: Clinical Grade Pulse Oximetry

What this connects to

Cardiovascular risk is not a self-contained system. Insulin resistance drives atherosclerosis, which is why nutrition and metabolic health sits upstream of much of what happens in the arteries. Poor sleep raises blood pressure and degrades glucose control within days. The gut microbiome produces metabolites that reach cardiac tissue directly.

The overlap with brain health is closer than most people realize. The vasculature that supplies the heart also supplies the brain, and vascular contribution to cognitive decline is substantial. Interventions that protect one organ tend to protect the other.

In the Four Villains of Health and Longevity, cardiovascular disease is the Silent Assassin. The name reflects its defining characteristic: it does its work for decades without symptoms, and for a large number of people the first sign is also the most serious one.

Frequently asked questions

What is Lp(a) and should I be tested?

Lipoprotein(a) is an LDL-like particle whose level is set almost entirely by genetics and is not meaningfully changed by diet, exercise, or statins. Roughly one in five people carries an elevated level, and it independently raises risk of atherosclerotic disease and aortic stenosis. Because the level is stable for life, one test is sufficient. The 2026 ACC/AHA guidelines moved toward routine measurement.

What does a coronary artery calcium score actually tell you?

It measures calcified plaque in your coronary arteries using a low-dose CT scan. Unlike a risk calculator, which estimates probability from population data, it reports whether disease is already present in you specifically. A score of zero carries a strongly favorable near-term prognosis and frequently reclassifies people the standard calculator rated as intermediate risk.

Is VO2 max really a better predictor than cholesterol?

For all-cause mortality, the evidence suggests yes. Analyses spanning millions of person-years found cardiorespiratory fitness predicted mortality more strongly than traditional risk factors. The largest single benefit appears when moving from the lowest fitness category to the next one, meaning the steepest gains are available to the least fit.

Does sauna use actually reduce cardiovascular risk?

Finnish cohort data spanning more than two decades shows a strong dose-dependent association between sauna frequency and lower cardiovascular mortality. The likely mechanism is that heat exposure mimics moderate exercise through raised heart rate, vessel dilation, and heat shock protein induction. The evidence is observational, so causation is not established, though the dose response is consistent.

Can a smartwatch detect atrial fibrillation reliably?

FDA-cleared consumer ECG devices detect atrial fibrillation with reasonable accuracy, and because AFib is often asymptomatic while substantially raising stroke risk, early detection genuinely changes outcomes. These devices screen rather than diagnose. An abnormal reading warrants clinical confirmation, not self-treatment.

Why do people with normal cholesterol still have heart attacks?

Standard panels do not capture several independent risk pathways. Lp(a) is genetically determined and unaffected by statins. Clonal hematopoiesis drives risk through inflammation originating in blood stem cells. Plaque burden already present is invisible to a lipid panel. Each sits outside what conventional cholesterol testing measures.

What single change most reduces cardiovascular risk?

For most people, improving cardiorespiratory fitness, particularly if currently sedentary, since the steepest mortality benefit occurs at the lowest fitness levels. That said, someone with untreated elevated Lp(a) or existing plaque may gain more from targeted medical management. This is the argument for measuring your own risk rather than applying population averages.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.